MET-driven papillary type-1 RCC: cabozantinib superior to sunitinib in MET-driven pRCC (P...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MET-AMP-RCC-PAPILLARY |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-RCC |
| Sources | SRC-CIVIC SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Actionability Facts
| Biomarker | BIO-MET |
|---|---|
| Variant | amplification or activating mutation (papillary type-1 context) |
| Disease | DIS-RCC |
| ESCAT tier | IIA |
| Recommended combinations | cabozantinib monotherapy (preferred for MET-driven pRCC type-1), savolitinib (trial / off-label) |
| Contraindicated monotherapy | sunitinib (inferior in MET-driven pRCC per PAPMET) |
| Evidence summary | MET-driven papillary type-1 RCC: cabozantinib superior to sunitinib in MET-driven pRCC (PAPMET / SWOG-1500, Pal 2021 — PFS 9.0 vs 5.6 mo in MET-driven cohort). Savolitinib (selective MET-TKI) showed activity in MET-driven papillary RCC (SAVOIR phase 3 closed early for futility vs sunitinib but signal in MET-driven subset). |
Notes
ESCAT IIA. OncoKB рівень 2. Зауваження: DIS-RCC — парасолькова сутність (окремої DIS-RCC-PAPILLARY немає); виокремлення папілярного типу 1 фіксується у полях variant_qualifier і notes. Прогалина джерел: SRC-PAPMET / SRC-SAVOIR ще не інгестовано.
Used By
No reverse references found in the YAML corpus.